BioLife Solutions, Inc. Net Income (Loss) Available to Common Stockholders, Diluted
BioLife Solutions, Inc. (BLFS) reported Net Income (Loss) Available to Common Stockholders, Diluted of -$15.84 million for the 3-month period ending 2025-06-30, per its 10-Q filed 2025-08-07.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2025-08-07
- BioLife Solutions, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2025-06-30 was -$15.84M.
- BioLife Solutions, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2025-03-31 was -$448.00K.
- BioLife Solutions, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2024-09-30 was -$1.70M.
- BioLife Solutions, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2024-06-30 was -$20.72M.
- BioLife Solutions, Inc. net income (loss) available to common stockholders, diluted for fiscal 2023 was -$66.43M.
- BioLife Solutions, Inc. net income (loss) available to common stockholders, diluted for fiscal 2022 was -$139.81M.
- BioLife Solutions, Inc. net income (loss) available to common stockholders, diluted for fiscal 2021 was -$8.91M.
- BioLife Solutions, Inc. net income (loss) available to common stockholders, diluted for fiscal 2020 was -$1.63M.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 3 month as first filed | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 6 month as first filed | Net Income (Loss) Available to Common Stockholders, Diluted 9 month | Net Income (Loss) Available to Common Stockholders, Diluted 9 month as first filed | Net Income (Loss) Available to Common Stockholders, Diluted 12 month | Net Income (Loss) Available to Common Stockholders, Diluted 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2025-06-30 | -$15.84M 10-Q · filed 2025-08-07 | -$16.29M 10-Q · filed 2025-08-07 | ||||||
| 2025-03-31 | -$448.00K 10-Q · filed 2025-05-08 | |||||||
| 2024-09-30 | -$1.70M 10-Q · filed 2024-11-12 | -$22.42M derived: sum of 2 quarters · filed 2025-08-07 | -$32.64M 10-Q · filed 2024-11-12 | -$46.02M derived: sum of 4 quarters · filed 2025-08-07 | ||||
| 2024-06-30 | -$20.72M 10-Q · filed 2025-08-07 | -$30.94M 10-Q · filed 2025-08-07 | -$44.32M derived: sum of 3 quarters · filed 2025-08-07 | -$73.45M derived: sum of 4 quarters · filed 2025-08-07 | ||||
| 2024-03-31 | -$10.22M 10-Q · filed 2025-05-08 | -$23.60M derived: sum of 2 quarters · filed 2025-05-08 | -$52.73M derived: sum of 3 quarters · filed 2025-05-08 | -$62.93M derived: sum of 4 quarters · filed 2025-05-08 | ||||
| 2023-12-31 | -$13.38M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | -$42.51M derived: sum of 2 quarters · filed 2024-11-12 | -$52.71M derived: sum of 3 quarters · filed 2024-11-12 | -$66.43M 10-K · filed 2024-02-29 | ||||
| 2023-09-30 | -$29.13M 10-Q · filed 2024-11-12 | -$39.33M derived: sum of 2 quarters · filed 2024-11-12 | -$53.05M 10-Q · filed 2024-11-12 | -$102.23M derived: sum of 4 quarters · filed 2024-11-12 | ||||
| 2023-06-30 | -$10.20M 10-Q · filed 2024-08-09 | -$23.91M 10-Q · filed 2024-08-09 | -$73.10M derived: sum of 3 quarters · filed 2024-08-09 | -$83.42M derived: sum of 4 quarters · filed 2024-08-09 | ||||
| 2023-03-31 | -$13.71M 10-Q · filed 2024-05-10 | -$62.90M derived: sum of 2 quarters · filed 2024-05-10 | -$73.22M derived: sum of 3 quarters · filed 2024-05-10 | -$146.10M derived: sum of 4 quarters · filed 2024-05-10 | ||||
| 2022-12-31 | -$49.19M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | -$59.51M derived: sum of 2 quarters · filed 2024-02-29 | -$132.38M derived: sum of 3 quarters · filed 2024-02-29 | -$139.81M 10-K · filed 2024-02-29 | ||||
| 2022-09-30 | -$10.32M 10-Q · filed 2023-11-09 | -$9.96M 10-Q · filed 2022-11-09 | -$83.19M derived: sum of 2 quarters · filed 2023-11-09 | -$90.62M 10-Q · filed 2023-11-09 | -$89.58M 10-Q · filed 2022-11-09 | |||
| 2022-06-30 | -$72.88M 10-Q · filed 2023-08-09 | -$72.55M 10-Q · filed 2022-08-09 | -$80.30M 10-Q · filed 2023-08-09 | -$79.62M 10-Q · filed 2022-08-09 | ||||
| 2021-12-31 | -$15.54M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | -$15.46M derived: sum of 2 quarters · filed 2024-02-29 | -$7.79M derived: sum of 3 quarters · filed 2024-02-29 | -$8.91M 10-K · filed 2024-02-29 | -$7.63M 10-K · filed 2022-03-31 | |||
| 2021-09-30 | $77.00K 10-Q · filed 2022-11-09 | $7.75M derived: sum of 2 quarters · filed 2022-11-09 | $6.63M 10-Q · filed 2022-11-09 | $4.72M derived: sum of 4 quarters · filed 2023-03-31 | ||||
| 2021-06-30 | $7.67M 10-Q · filed 2022-08-09 | $6.55M 10-Q · filed 2022-08-09 | $4.64M derived: sum of 3 quarters · filed 2023-03-31 | $3.51M derived: sum of 4 quarters · filed 2023-03-31 | ||||
| 2021-03-31 | -$1.12M 10-Q · filed 2021-05-17 | -$3.03M derived: sum of 2 quarters · filed 2023-03-31 | -$4.16M derived: sum of 3 quarters · filed 2023-03-31 | -$20.54M derived: sum of 4 quarters · filed 2023-03-31 | ||||
| 2020-12-31 | -$1.91M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | -$3.04M derived: sum of 2 quarters · filed 2023-03-31 | -$19.42M derived: sum of 3 quarters · filed 2023-03-31 | -$1.63M 10-K · filed 2023-03-31 | -$954.00K 10-K · filed 2021-03-31 | |||
| 2020-09-30 | -$1.13M 10-Q · filed 2021-11-15 | -$17.51M derived: sum of 2 quarters · filed 2021-11-15 | $279.00K 10-Q · filed 2021-11-15 | -$14.70M derived: sum of 4 quarters · filed 2022-03-31 | ||||
| 2020-06-30 | -$16.38M 10-Q · filed 2021-08-16 | $350.00K 10-Q · filed 2021-08-16 | -$13.57M derived: sum of 3 quarters · filed 2022-03-31 | -$4.71M derived: sum of 4 quarters · filed 2022-03-31 | ||||
| 2020-03-31 | -$174.00K 10-Q · filed 2021-05-17 | $2.81M derived: sum of 2 quarters · filed 2022-03-31 | $11.67M derived: sum of 3 quarters · filed 2022-03-31 | $12.22M derived: sum of 4 quarters · filed 2022-03-31 | ||||
| 2019-12-31 | $2.98M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $11.85M derived: sum of 2 quarters · filed 2022-03-31 | $12.39M derived: sum of 3 quarters · filed 2022-03-31 | -$1.66M 10-K · filed 2022-03-31 | ||||
| 2019-09-30 | $8.86M 10-Q · filed 2020-11-09 | $9.41M derived: sum of 2 quarters · filed 2020-11-09 | -$4.64M 10-Q · filed 2020-11-09 | |||||
| 2019-06-30 | $545.00K 10-Q · filed 2020-08-10 | -$14.91M 10-Q · filed 2020-08-10 | ||||||
| 2019-03-31 | -$19.16M 10-Q · filed 2020-05-29 | |||||||
| 2018-09-30 | -$24.55M 10-K · filed 2020-05-15 | -$50.98M derived: sum of 2 quarters · filed 2020-05-15 | -$46.22M 10-K · filed 2020-05-15 | |||||
| 2018-06-30 | -$26.44M 10-K · filed 2020-05-15 | -$21.67M 10-K · filed 2020-05-15 | ||||||
| 2018-03-31 | -$282.00K 10-K · filed 2020-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Axogen, Inc. (AXGN) | United States | $2.329B | -73.83 |
| CONMED Corp (CNMD) | United States | $1.353B | 26.72 |
| Ceribell, Inc. (CBLL) | United States | $0.916B | -11.27 |
| TransMedics Group, Inc. (TMDX) | United States | $2.911B | 15.17 |
| CapsoVision, Inc (CV) | United States | $0.310B | -12.68 |
| Electromed, Inc. (ELMD) | United States | $0.233B | 31.13 |
| EDAP TMS SA (FOCL) | $0.171B | ||
| Stereotaxis, Inc. (STXS) | United States | $0.130B | -7.53 |
| Vivani Medical, Inc. (VANI) | United States | $0.111B | |
| electroCore, Inc. (ECOR) | United States | $0.102B |